keyboard_arrow_up

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H1 2015

RnRMarketResearch adds ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2015’ to its store. This report provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects.

Some of the Company profiles mentioned in this report are Actinium Pharmaceuticals, Altor BioScience Corporation, Ariad Pharmaceuticals, Astex Pharmaceuticals, Celator Pharmaceuticals, Cellular Biomedicine Group, Epirus Biopharmaceuticals, Formula Pharmaceuticals, Johnson & Johnson, Sigma-Tau Pharmaceuticals, Syndax Pharmaceuticals, Threshold Pharmaceuticals, Tragara Pharmaceuticals.

Get a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=403538 . (This is a premium report price at US$2000 for a single user PDF license)

 Scope

- The report reviews key players involved in the therapeutics development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and enlists all their major and minor projects

- The report summarizes all the dormant and discontinued pipeline projects

- A review of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- A detailed assessment of monotherapy and combination therapy pipeline projects

- Coverage of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline on the basis of target, MoA, route of administration and molecule type

- Latest news and deals relating related to pipeline products

Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.